サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427698

抗生物質耐性の世界市場レポート 2024

Antibiotic Resistance Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
抗生物質耐性の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

抗生物質耐性の市場規模は、今後数年間で大幅な成長が見込まれています。2028年には6.3%の年間複合成長率（CAGR）で154億7,000万米ドルに成長すると予想されます。予測期間の増加は、不完全な治療コース、国際化と旅行、不十分な感染予防と制御、セルフメディケーション、種間感染、高い人口密度などの要因に起因すると考えられます。予測期間の主な動向には、ドラッグデリバリーにおける技術革新、監視のための世界の協力、人工知能の役割の拡大、新しい治療法の急増が含まれます。

薬剤耐性感染症の急増は、抗生物質耐性市場拡大の重要な促進力になると予想されます。薬剤に耐性のある細菌によって引き起こされるこれらの感染症は、それが引き起こす病気の治癒や治療に課題をもたらします。抗菌薬耐性薬は、さまざまな薬剤耐性感染症の管理において重要な役割を果たし、標的病原体と非標的病原体の両方に対する治療成績を向上させます。欧州疾病予防管理センターが提供した2022年11月の例では、EU/EEAでは毎年約35,000人が抗菌薬耐性疾患で死亡していることが浮き彫りになりました。さらに、肺炎桿菌感染症の症例は2021年に20%増加し、カンジダ・アウリスの報告症例数は2020年から2021年にかけてほぼ2倍となり、薬剤耐性感染症の蔓延による抗生物質耐性市場の促進力であることが強調されました。

ヘルスケア費の高騰により、抗生物質耐性市場の成長軌道が加速する傾向にあります。ヘルスケア支出とは、指定された期間内に医療関連の商品やサービスに投資された累積財源を指します。ヘルスケア支出の増加は、抗生物質耐性感染症によってもたらされる課題に対抗するための革新的な治療法の調査、開発、導入の促進を促進することにより、抗生物質耐性市場を推進する上で極めて重要な役割を果たします。特に、メディケア・メディケイドサービスセンターが2022年3月に発表した2021年から2030年の国民医療支出（NHE）報告書によると、2021年から2030年までの国民医療支出の推定年間成長率は5.1％で、その額は6兆8,000億米ドル近くに達するとの予測が示されています。さらに、2021年から2030年までにメディケア支出が7.2%、メディケイド支出が5.6%と予想される年間成長率は、ヘルスケア支出の増加が抗生物質耐性市場の拡大に大きく寄与していることを強調しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の抗生物質耐性市場の促進要因と抑制要因
    • 市場の促進要因
    • 市場の抑制要因
  • 世界の抗生物質耐性の市場規模実績と成長、2018年～2023年
  • 世界の抗生物質耐性の市場規模と成長予測、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の抗生物質耐性市場、薬剤クラス別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • ベータラクタム抗生物質
  • セファロスポリン類
  • キノロン系抗生物質
  • マクロライド系抗生物質
  • テトラサイクリン系
  • オキサゾリジノン
  • 他の薬物クラス
  • 世界の抗生物質耐性市場、病原体別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 黄色ブドウ球菌
  • 肺炎球菌
  • 淋菌
  • エンテロコッカス・フェシウム
  • 大腸菌
  • クレブシエラ肺炎
  • 赤ブドウ球菌
  • クロストリジウム・ディフィシル
  • その他の病原体
  • 世界の抗生物質耐性市場、疾患タイプ別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 尿路感染
  • 腹腔内感染症
  • 血流感染症、
  • クロストリジウム・ディフィシル感染症
  • その他の病気の種類
  • 世界の抗生物質耐性市場、作用機序別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • タンパク質合成阻害剤
  • 細胞壁合成阻害剤
  • RNA合成阻害剤
  • DNA合成阻害剤
  • その他の作用機序
  • 世界の抗生物質耐性市場、エンドユーザー別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 病院
  • ホームケア
  • 専門クリニック
  • その他のエンドユーザー

第7章 地域と国の分析

  • 世界の抗生物質耐性市場、地域別、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 世界の抗生物質耐性市場、国別、実績と予測、2018年～2023年、2023年～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 抗生物質耐性市場の競合情勢
  • 抗生物質耐性市場の企業プロファイル
    • Pfizer Inc.
    • Johnson and Johnson
    • F. Hoffmann-La Roche Ltd
    • AbbVie Inc.
    • Novartis AG

第31章 その他の大手と革新的な企業

  • Merck and Co. Inc.
  • Bristol-Myers Squibb
  • Sanofi SA
  • Thermo Fisher Scientific Inc
  • AstraZeneca
  • GlaxoSmithKline Plc
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Astellas Pharma
  • Daiichi Sankyo
  • Chugai Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Bio-Rad Laboratories Inc
  • Eppendorf Corporation
  • Takara Bio Inc

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13542

Antimicrobial resistance refers to the phenomenon where microorganisms, including bacteria and fungi, develop the ability to withstand the effects of medications designed to eliminate them. This resistance poses a significant challenge in the treatment of infections and, in severe cases, can lead to fatalities.

The primary classes of drugs associated with antibiotic resistance include beta-lactam antibiotics, cephalosporins, quinolone antibiotics, macrolide antibiotics, tetracyclines, oxazolidinones, and others. Beta-lactam antibiotics, characterized by a beta-lactam ring in their chemical structure, work by preventing the construction of bacterial cell walls. They achieve this by covalently binding to crucial penicillin-binding proteins (PBPs), inhibiting the growth of organisms. Pathogens affected by these drugs include Staphylococcus aureus, Staphylococcus pneumonia, Neisseria gonorrhoeae, Enterococcus faecium, Escherichia coli, Klebsiella pneumonia, Shigella, Clostridium difficile, among others. These drugs are employed in the treatment of various diseases such as urinary tract infections, intra-abdominal infections, bloodstream infections, and Clostridium difficile infections. The mechanisms of action encompass protein synthesis inhibitors, cell wall synthesis inhibitors, RNA synthesis inhibitors, DNA synthesis inhibitors, and others. These drugs are utilized by diverse end-users, including hospitals, homecare, specialty clinics, and more.

The antibiotic resistance market research report is one of a series of new reports from The Business Research Company that provides antibiotic resistance market statistics, including the antibiotic resistance industry global market size, regional shares, competitors with an antibiotic resistance market share, detailed antibiotic resistance market segments, market trends, and opportunities, and any further data you may need to thrive in the antibiotic resistance industry. This antibiotic resistance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antibiotic resistance market size has grown strongly in recent years. It will grow from $11.43 billion in 2023 to $12.13 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to several factors, including the absence of new antibiotics, the misuse and overuse of antimicrobials in humans, animals, and plants, highly contaminated waste effluents, low vaccination rates, and a lack of diagnostic tools.

The antibiotic resistance market size is expected to see strong growth in the next few years. It will grow to $15.47 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to factors such as incomplete treatment courses, globalization and travel, poor infection prevention and control, self-medication, cross-species transmission, and high population density. Major trends in the forecast period include technological innovations in drug delivery, global collaboration for surveillance, expanding the role of artificial intelligence, and a surge in novel therapies.

The surge in drug-resistant infections is anticipated to be a significant driver for the expansion of the antibiotic-resistance market. These infections, caused by bacteria resistant to drugs, pose challenges in curing or treating the diseases they cause. Antimicrobial resistance drugs play a crucial role in managing various drug-resistant infections, improving treatment outcomes for both target and non-target pathogens. An example from November 2022, provided by the European Centre for Disease Prevention and Control, highlighted that approximately 35,000 individuals in the EU/EEA succumb annually to antimicrobial-resistant diseases. Furthermore, instances of Klebsiella pneumoniae infections increased by 20% in 2021, and reported cases of Candida auris nearly doubled between 2020 and 2021, emphasizing the driving force behind the antibiotic resistance market due to the prevalence of drug-resistant infections.

The escalation in healthcare expenditure is poised to fuel the growth trajectory of the antibiotic resistance market. Healthcare expenditure denotes the cumulative financial resources invested in healthcare-related goods and services within a specified timeframe. Increased healthcare spending plays a pivotal role in propelling the antibiotic resistance market by fostering heightened research, development, and adoption of innovative treatments to counter the challenges posed by antibiotic-resistant infections. Notably, as per the 2021-2030 National Health Expenditure (NHE) report released by the Centers for Medicare & Medicaid Services in March 2022, projections indicate an estimated annual growth rate of 5.1% in national health spending between 2021 and 2030, reaching nearly $6.8 trillion. Moreover, the anticipated annual growth rates of 7.2% for Medicare spending and 5.6% for Medicaid spending from 2021 to 2030 underscore the substantial contribution of growing healthcare expenditure to the expansion of the antibiotic resistance market.

The antibiotic resistance market is witnessing a prominent trend centered on product innovations. Key players within this market are dedicated to pioneering innovative products to solidify their market presence. For instance, in January 2023, Alkem Laboratories Limited, an India-based pharmaceutical firm, introduced Zidavi. This novel antibiotic, a combination of ceftazidime and avibactam, addresses multi-drug resistant (MDR) infections, ensuring accessibility, affordability, and availability for critically ill patients. Zidavi, available in sterile powdered concentrate for reconstitution, offers a distinctive solution for treating infections caused by MDR gram-negative pathogens. Its formulation in single-dose vials provides an effective alternative for treating hospital-acquired pneumonia (HAP) and severe intra-abdominal infections (IAIs) linked to meropenem and colistin resistance.

Major enterprises in the antibiotic resistance market are strategically fostering partnerships to innovate and create the next generation of antimicrobial agents alongside practical diagnostics in the fight against Antimicrobial Resistance (AMR). These strategic collaborations involve leveraging complementary strengths and resources to achieve mutual success. For example, in July 2022, Boehringer Ingelheim, a Germany-based pharmaceutical company, and Evotec SE, a German biotechnology firm, joined forces with bioMerieux, a France-based diagnostic solutions provider. This partnership resulted in the formation of Aurobac Therapeutics SAS, aiming to pioneer a novel precision medicine strategy spanning diagnosis to treatment by harnessing the collective expertise of the founding companies. Their collaborative efforts aim to develop innovative antimicrobials coupled with effective diagnostics to counter the challenge posed by Antimicrobial Resistance (AMR).

In July 2022, Innoviva Inc., a pharmaceutical company based in the United States, successfully acquired Entasis Therapeutics Holdings Inc for an undisclosed sum. This strategic acquisition is designed to enhance Innoviva Inc's product portfolio focused on addressing multidrug-resistant gram-negative bacteria, providing a competitive edge in the market. Entasis Therapeutics Holdings Inc., a US-based company, specializes in the development of innovative antibacterial solutions for the treatment of severe bacterial infections resistant to conventional drugs.

Major companies operating in the antibiotic resistance market report are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Merck and Co. Inc., Bristol-Myers Squibb, Sanofi S.A., Thermo Fisher Scientific Inc., AstraZeneca, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Bio-Rad Laboratories Inc., Eppendorf Corporation, Takara Bio Inc., Wockhardt Ltd., Paratek Pharmaceuticals Inc., Basilea Pharmaceutica Ltd., Theravance Biopharma Inc., Nabriva Therapeutics PLC, Seres Therapeutics Inc., Armata Pharmaceuticals Inc.

North America was the largest region in the antibiotic resistance market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibiotic resistance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antibiotic resistance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antibiotic resistance market consists of sales of antibiotic drug classes such as carbapenems, glycopeptide antibiotics, penicillin, fluoroquinolones, trimethoprim-sulfamethoxazole, lincosamides, aminoglycosides, polymyxins, and nitroimidazoles. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antibiotic Resistance Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antibiotic resistance market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antibiotic resistance ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antibiotic resistance market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug Class: Beta Lactum Antibiotic; Cephalosporins; Quinolones Antibiotics; Macrolide Antibiotics; Tetracyclines; Oxazolidinones; Other Drug Classes
  • 2) By Pathogen: Staphylococcus aureus; Staphylococcus pneumonia; Neisseria gonorrhoeae; Enterococcus Faecium; Escherichia coli; Klebsiella pneumonia; Shigella; Clostridium difficile; Other pathogens
  • 3) By Disease Type: Urinary tract infection; Intra-abdominal infection; Blood stream infections; Clostridium difficile infections; Other Disease Types
  • 4) By Mechanism of Action: Protein Synthesis Inhibitors; Cell Wall Synthesis Inhibitors; RNA Synthesis Inhibitors; DNA Synthesis Inhibitors; Other Mechanism Of Actions
  • 5) By End Users: Hospitals; Homecare; Specialty clinics; Other End-users
  • Companies Mentioned: Pfizer Inc.; Johnson and Johnson; F. Hoffmann-La Roche Ltd; AbbVie Inc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antibiotic Resistance Market Characteristics

3. Antibiotic Resistance Market Trends And Strategies

4. Antibiotic Resistance Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Antibiotic Resistance Market Size and Growth

  • 5.1. Global Antibiotic Resistance Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Antibiotic Resistance Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Antibiotic Resistance Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Antibiotic Resistance Market Segmentation

  • 6.1. Global Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Beta Lactum Antibiotic
  • Cephalosporins
  • Quinolones Antibiotics
  • Macrolide Antibiotics
  • Tetracyclines
  • Oxazolidinones
  • Other Drug Classes
  • 6.2. Global Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Staphylococcus aureus
  • Staphylococcus pneumonia
  • Neisseria gonorrhoeae
  • Enterococcus Faecium
  • Escherichia coli
  • Klebsiella pneumonia
  • Shigella
  • Clostridium difficile
  • Other pathogens
  • 6.3. Global Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Urinary tract infection
  • Intra-abdominal infection
  • Blood stream infections,
  • Clostridium difficile infections
  • Other Disease Type
  • 6.4. Global Antibiotic Resistance Market, Segmentation By Mechanism of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Protein Synthesis Inhibitors
  • Cell Wall Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • Other Mechanism of actions
  • 6.5. Global Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End-users

7. Antibiotic Resistance Market Regional And Country Analysis

  • 7.1. Global Antibiotic Resistance Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Antibiotic Resistance Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Antibiotic Resistance Market

  • 8.1. Asia-Pacific Antibiotic Resistance Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Antibiotic Resistance Market

  • 9.1. China Antibiotic Resistance Market Overview
  • 9.2. China Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Antibiotic Resistance Market

  • 10.1. India Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Antibiotic Resistance Market

  • 11.1. Japan Antibiotic Resistance Market Overview
  • 11.2. Japan Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Antibiotic Resistance Market

  • 12.1. Australia Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Antibiotic Resistance Market

  • 13.1. Indonesia Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Antibiotic Resistance Market

  • 14.1. South Korea Antibiotic Resistance Market Overview
  • 14.2. South Korea Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Antibiotic Resistance Market

  • 15.1. Western Europe Antibiotic Resistance Market Overview
  • 15.2. Western Europe Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Antibiotic Resistance Market

  • 16.1. UK Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Antibiotic Resistance Market

  • 17.1. Germany Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Antibiotic Resistance Market

  • 18.1. France Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Antibiotic Resistance Market

  • 19.1. Italy Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Antibiotic Resistance Market

  • 20.1. Spain Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Antibiotic Resistance Market

  • 21.1. Eastern Europe Antibiotic Resistance Market Overview
  • 21.2. Eastern Europe Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Antibiotic Resistance Market

  • 22.1. Russia Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Antibiotic Resistance Market

  • 23.1. North America Antibiotic Resistance Market Overview
  • 23.2. North America Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Antibiotic Resistance Market

  • 24.1. USA Antibiotic Resistance Market Overview
  • 24.2. USA Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Antibiotic Resistance Market

  • 25.1. Canada Antibiotic Resistance Market Overview
  • 25.2. Canada Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Antibiotic Resistance Market

  • 26.1. South America Antibiotic Resistance Market Overview
  • 26.2. South America Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Antibiotic Resistance Market

  • 27.1. Brazil Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Antibiotic Resistance Market

  • 28.1. Middle East Antibiotic Resistance Market Overview
  • 28.2. Middle East Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Antibiotic Resistance Market

  • 29.1. Africa Antibiotic Resistance Market Overview
  • 29.2. Africa Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Antibiotic Resistance Market Competitive Landscape And Company Profiles

  • 30.1. Antibiotic Resistance Market Competitive Landscape
  • 30.2. Antibiotic Resistance Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson and Johnson
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche Ltd
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AbbVie Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Antibiotic Resistance Market Other Major And Innovative Companies

  • 31.1. Merck and Co. Inc.
  • 31.2. Bristol-Myers Squibb
  • 31.3. Sanofi S.A.
  • 31.4. Thermo Fisher Scientific Inc
  • 31.5. AstraZeneca
  • 31.6. GlaxoSmithKline Plc
  • 31.7. Eli Lilly and Company
  • 31.8. Boehringer Ingelheim International GmbH
  • 31.9. Astellas Pharma
  • 31.10. Daiichi Sankyo
  • 31.11. Chugai Pharmaceutical Co. Ltd.
  • 31.12. Teva Pharmaceutical Industries Ltd.
  • 31.13. Bio-Rad Laboratories Inc
  • 31.14. Eppendorf Corporation
  • 31.15. Takara Bio Inc

32. Global Antibiotic Resistance Market Competitive Benchmarking

33. Global Antibiotic Resistance Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Antibiotic Resistance Market

35. Antibiotic Resistance Market Future Outlook and Potential Analysis

  • 35.1 Antibiotic Resistance Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Antibiotic Resistance Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Antibiotic Resistance Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer